Marksans Pharma Q2 FY25: Revenue up 20.84% YoY to Rs 641.92 crore, Net Profit up 16.56% YoY

Marksans Pharma Ltd. reported unaudited consolidated and standalone financial results for the quarter and half-year ended September 30, 2024.

Q2 FY25 financial analysis for Marksans Pharma with figures converted to crores:

Quarter-over-Quarter (QoQ) Comparison

Year-over-Year (YoY) Comparison

Revenue from Operations: ₹641.92 crore in Q2 FY25 vs ₹531.24 crore in Q2 FY24, a growth of 20.84%.
Net Profit: ₹97.76 crore in Q2 FY25 vs ₹83.87 crore in Q2 FY24, an increase of 16.56%.

Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.

Marksans Pharma